The synergistic effect with decitabine, described above, is promising evidence that PARP1 inhibitors could be used in patients with MDS in combination with hypomethylating agents such as decitabine or 5-azacytidine that constitute the standard of care for MDS. The gene discussed is PARP1; the disease is myelodysplastic syndrome.